Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
Identifieur interne : 000102 ( PubMed/Corpus ); précédent : 000101; suivant : 000103Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
Auteurs : Mohammad Rasheduzzaman ; Ji-Hong Moon ; Ju-Hee Lee ; Uddin Md Nazim ; Sang-Youel ParkSource :
- The international journal of biochemistry & cell biology [ 1878-5875 ] ; 2018.
English descriptors
- KwdEn :
- A549 Cells, AMP-Activated Protein Kinases (metabolism), Apoptosis (drug effects), Autophagy (drug effects), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Molecular Targeted Therapy, Phosphorylation (drug effects), Reactive Oxygen Species (metabolism), Receptors, TNF-Related Apoptosis-Inducing Ligand (metabolism), TNF-Related Apoptosis-Inducing Ligand (metabolism), Telmisartan (pharmacology), Telmisartan (therapeutic use), Up-Regulation (drug effects).
- MESH :
- chemical , metabolism : AMP-Activated Protein Kinases, Reactive Oxygen Species, Receptors, TNF-Related Apoptosis-Inducing Ligand, TNF-Related Apoptosis-Inducing Ligand.
- drug effects : Apoptosis, Autophagy, Phosphorylation, Up-Regulation.
- drug therapy : Lung Neoplasms.
- metabolism : Lung Neoplasms.
- pathology : Lung Neoplasms.
- chemical , pharmacology : Telmisartan.
- chemical , therapeutic use : Telmisartan.
- A549 Cells, Humans, Molecular Targeted Therapy.
Abstract
Telmisartan broadly used for the treatment of hypertension that is also known for its anticancer properties. TRAIL has the potential to kill tumor cells with minimal toxicity in normal cells by binding to death receptors, DR4 and DR5. Unfortunately, these TRAIL-death receptors have failed as most human cancers are resistant to TRAIL-mediated apoptosis. In this study, we evaluated telmisartan as a novel TRAIL-DR5-targeting agent with the aim of rendering TRAIL-based cancer therapies more active. Herein, we demonstrated that telmisartan could sensitize TRAIL and enhance NSCLC tumor cell death. The molecular mechanism includes the blocking of AMPK phosphorylation causes inhibition of autophagy flux by telmisartan resulting in ROS generation leading to death receptor (DR5) upregulation and subsequent activation of the caspase cascade by TRAIL treatment. Furthermore, using chloroquine and siATG5 significantly enhances ROS production and application of the ROS scavenger N-acetyl-cysteine (NAC) rescues the cells undergoing apoptosis by abrogating the expression of DR5 and finally the caspase cascade. Additionally, NAC treatment also maintains autophagy flux and makes the cells unresponsive to TRAIL. In summary, telmisartan in combination with TRAIL exhibits enhanced cytotoxic capacity toward lung cancer cells, thereby providing the potential for effective and novel therapeutic approaches to treat lung cancer.
DOI: 10.1016/j.biocel.2018.06.006
PubMed: 29929000
Links to Exploration step
pubmed:29929000Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.</title>
<author><name sortKey="Rasheduzzaman, Mohammad" sort="Rasheduzzaman, Mohammad" uniqKey="Rasheduzzaman M" first="Mohammad" last="Rasheduzzaman">Mohammad Rasheduzzaman</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moon, Ji Hong" sort="Moon, Ji Hong" uniqKey="Moon J" first="Ji-Hong" last="Moon">Ji-Hong Moon</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, Ju Hee" sort="Lee, Ju Hee" uniqKey="Lee J" first="Ju-Hee" last="Lee">Ju-Hee Lee</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nazim, Uddin Md" sort="Nazim, Uddin Md" uniqKey="Nazim U" first="Uddin Md" last="Nazim">Uddin Md Nazim</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Park, Sang Youel" sort="Park, Sang Youel" uniqKey="Park S" first="Sang-Youel" last="Park">Sang-Youel Park</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea. Electronic address: sypark@chonbuk.ac.kr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29929000</idno>
<idno type="pmid">29929000</idno>
<idno type="doi">10.1016/j.biocel.2018.06.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000102</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000102</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.</title>
<author><name sortKey="Rasheduzzaman, Mohammad" sort="Rasheduzzaman, Mohammad" uniqKey="Rasheduzzaman M" first="Mohammad" last="Rasheduzzaman">Mohammad Rasheduzzaman</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moon, Ji Hong" sort="Moon, Ji Hong" uniqKey="Moon J" first="Ji-Hong" last="Moon">Ji-Hong Moon</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, Ju Hee" sort="Lee, Ju Hee" uniqKey="Lee J" first="Ju-Hee" last="Lee">Ju-Hee Lee</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nazim, Uddin Md" sort="Nazim, Uddin Md" uniqKey="Nazim U" first="Uddin Md" last="Nazim">Uddin Md Nazim</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Park, Sang Youel" sort="Park, Sang Youel" uniqKey="Park S" first="Sang-Youel" last="Park">Sang-Youel Park</name>
<affiliation><nlm:affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea. Electronic address: sypark@chonbuk.ac.kr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">The international journal of biochemistry & cell biology</title>
<idno type="eISSN">1878-5875</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A549 Cells</term>
<term>AMP-Activated Protein Kinases (metabolism)</term>
<term>Apoptosis (drug effects)</term>
<term>Autophagy (drug effects)</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Molecular Targeted Therapy</term>
<term>Phosphorylation (drug effects)</term>
<term>Reactive Oxygen Species (metabolism)</term>
<term>Receptors, TNF-Related Apoptosis-Inducing Ligand (metabolism)</term>
<term>TNF-Related Apoptosis-Inducing Ligand (metabolism)</term>
<term>Telmisartan (pharmacology)</term>
<term>Telmisartan (therapeutic use)</term>
<term>Up-Regulation (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>AMP-Activated Protein Kinases</term>
<term>Reactive Oxygen Species</term>
<term>Receptors, TNF-Related Apoptosis-Inducing Ligand</term>
<term>TNF-Related Apoptosis-Inducing Ligand</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Autophagy</term>
<term>Phosphorylation</term>
<term>Up-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Telmisartan</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Telmisartan</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>A549 Cells</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Telmisartan broadly used for the treatment of hypertension that is also known for its anticancer properties. TRAIL has the potential to kill tumor cells with minimal toxicity in normal cells by binding to death receptors, DR4 and DR5. Unfortunately, these TRAIL-death receptors have failed as most human cancers are resistant to TRAIL-mediated apoptosis. In this study, we evaluated telmisartan as a novel TRAIL-DR5-targeting agent with the aim of rendering TRAIL-based cancer therapies more active. Herein, we demonstrated that telmisartan could sensitize TRAIL and enhance NSCLC tumor cell death. The molecular mechanism includes the blocking of AMPK phosphorylation causes inhibition of autophagy flux by telmisartan resulting in ROS generation leading to death receptor (DR5) upregulation and subsequent activation of the caspase cascade by TRAIL treatment. Furthermore, using chloroquine and siATG5 significantly enhances ROS production and application of the ROS scavenger N-acetyl-cysteine (NAC) rescues the cells undergoing apoptosis by abrogating the expression of DR5 and finally the caspase cascade. Additionally, NAC treatment also maintains autophagy flux and makes the cells unresponsive to TRAIL. In summary, telmisartan in combination with TRAIL exhibits enhanced cytotoxic capacity toward lung cancer cells, thereby providing the potential for effective and novel therapeutic approaches to treat lung cancer.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29929000</PMID>
<DateCompleted><Year>2019</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5875</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>102</Volume>
<PubDate><Year>2018</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>The international journal of biochemistry & cell biology</Title>
<ISOAbbreviation>Int. J. Biochem. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.</ArticleTitle>
<Pagination><MedlinePgn>20-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1357-2725(18)30142-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biocel.2018.06.006</ELocationID>
<Abstract><AbstractText>Telmisartan broadly used for the treatment of hypertension that is also known for its anticancer properties. TRAIL has the potential to kill tumor cells with minimal toxicity in normal cells by binding to death receptors, DR4 and DR5. Unfortunately, these TRAIL-death receptors have failed as most human cancers are resistant to TRAIL-mediated apoptosis. In this study, we evaluated telmisartan as a novel TRAIL-DR5-targeting agent with the aim of rendering TRAIL-based cancer therapies more active. Herein, we demonstrated that telmisartan could sensitize TRAIL and enhance NSCLC tumor cell death. The molecular mechanism includes the blocking of AMPK phosphorylation causes inhibition of autophagy flux by telmisartan resulting in ROS generation leading to death receptor (DR5) upregulation and subsequent activation of the caspase cascade by TRAIL treatment. Furthermore, using chloroquine and siATG5 significantly enhances ROS production and application of the ROS scavenger N-acetyl-cysteine (NAC) rescues the cells undergoing apoptosis by abrogating the expression of DR5 and finally the caspase cascade. Additionally, NAC treatment also maintains autophagy flux and makes the cells unresponsive to TRAIL. In summary, telmisartan in combination with TRAIL exhibits enhanced cytotoxic capacity toward lung cancer cells, thereby providing the potential for effective and novel therapeutic approaches to treat lung cancer.</AbstractText>
<CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rasheduzzaman</LastName>
<ForeName>Mohammad</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moon</LastName>
<ForeName>Ji-Hong</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Ju-Hee</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nazim</LastName>
<ForeName>Uddin Md</ForeName>
<Initials>UM</Initials>
<AffiliationInfo><Affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Sang-Youel</ForeName>
<Initials>SY</Initials>
<AffiliationInfo><Affiliation>Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Iksan, Jeonbuk 54596, South Korea. Electronic address: sypark@chonbuk.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>06</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Biochem Cell Biol</MedlineTA>
<NlmUniqueID>9508482</NlmUniqueID>
<ISSNLinking>1357-2725</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053220">Receptors, TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.31</RegistryNumber>
<NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>U5SYW473RQ</RegistryNumber>
<NameOfSubstance UI="D000077333">Telmisartan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053220" MajorTopicYN="N">Receptors, TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077333" MajorTopicYN="N">Telmisartan</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Apoptosis</Keyword>
<Keyword MajorTopicYN="Y">Autophagy</Keyword>
<Keyword MajorTopicYN="Y">DR5</Keyword>
<Keyword MajorTopicYN="Y">ROS</Keyword>
<Keyword MajorTopicYN="Y">TRAIL</Keyword>
<Keyword MajorTopicYN="Y">Telmisartan</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>04</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>06</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>06</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29929000</ArticleId>
<ArticleId IdType="pii">S1357-2725(18)30142-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.biocel.2018.06.006</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:29929000 |texte= Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29929000" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |